Any news on the entinostat trials?

Daniel86

I read there is (or was) an active trial in quite a few locations with entinostat + exemestane in phase III. Anyone from the boards taking part/knowing someone who is? It really sounded promising from the little literature available out there. It's so frustrating to have to wait years to know anything.

https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2014-00746&r=1

They are also tweaking with immonutherapy

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-announces-clinical-collaboration-to-evaluate-entinostat-in-combination-with-anti-pd-l1-cancer-immunotherapy-in-breast-cancer-300580481.html

Cure-ious

Excellent question, Danei86! I had forgotten about entinostat, one of a new class of epigenetic regulator drugs.

There was a report in PubMed last Jan saying that in phase 2, after progression on Femara-Ibrance or equivalent, patients who went onto entinostat plus exemestane got a paltry increase in progression-free survival, like from 2+ months on exemestane alone to 5+ monthis on exemestane plus entinostat. So no big shakes. But, what was surprising, was an 8 month benefit in overall survival, which is normally really hard to show any benefit! suggesting that the change in epigenetic status of the cancer or the immune system may be having a longer-term effect on subsequent treatment regimens? not sure what it means, but exposure to this agent may have made subsequent chemo more effective?

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC57650...

They are into phase III right now, so we should get some hard numbers soon. It's a hard one to sequence, because you would still need to be sensitive to anti-hormonals, so it would have to be in relatively early in the lineup, but the progression free survival numbers don't look great compared to something like a Faslodex-Ibrance combo, let alone what that might be if they added some immunotherapy.mThe entinostat- atezoluzumab combo might be promising, at least atezo is one of the strongest checkpoint inhibitors.